Palisade Bio completes all five SAD cohorts, advanced MAD cohorts for PALI-2108

lisade Bio announced the completion of all five planned Single Ascending Dose, SAD, cohorts and the commencement of the Multiple Ascending Dose cohorts in its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis, UC. Preliminary data from the SAD portion of the study, which evaluated doses ranging from 15 mg to 450 mg of PALI-2108, support that the drug was well-tolerated across all dose levels. Importantly, there were no treatment-related dose reductions, serious adverse events, SAEs, or treatment-related laboratory abnormalities observed. Treatment-emergent adverse events , TEASs, were mild and occurred only at the highest dose of 450 mg. Importantly, there were no EKG abnormalities or other serious safety concerns, underscoring the favorable safety profile of PALI-2108.